|
Suppliers for CAS
1225278-16-9
|
Properties | | CAS |
1225278-16-9 | | Formula |
C26H21F2N5O3 |
|
5 Registered suppliers
Amadis Chemical Company Limited
P.R.China
More details are to be found here
Leap Chem Co., Ltd
P.R.China
Molecular Formula: C26H21F2N5O3
Molecular Weight: 489.4734464
Aea.ltd
P.R.China
Molecular Formula: C26H21F2N5O3
Molecular Weight: 489.4734464
BOC Sciences
USA
Description : DCC-2618 inhibits normal and mutant KIT kinase at the nanomol level. The targets are wt c-KIT, c-KIT mutants, PDGFR alpha, PDGFR beta, KDR and cFMS. DCC-2618 inhibits mutant KIT in GIST patient cell line (GIST T1 pKIT western Ex11 deletion) at a IC 50 of 2 nM. Deciphera's technology has identified DCC-2618 as a molecule which can be developed as second line therapy for imatinib and sunitinib resistant GIST patients with the potential to progress to frontline GIST therapy. DCC-2618 has been designed to effectively inhibit the imatinib and sunitinib-sensitive KIT juxtamembrane domain mutants (JMD) as well as secondary resistant KIT kinase-domain mutants. DCC-2618 additionally targets PDGFR alpha oncogenic mutants. - Molecular Weight :489.47
- Boiling Point :729.7±60.0 °C at 760 mmHg
- Purity :> 98%
Molecular Formula : C26H21F2N5O3 Canonical SMILES : CN1C=C(C=N1)C2=NC=CC(=C2)OC3=C(C=C(C(=C3)F)NC(=O)C4(CC4)C(=O)NC5=CC=CC=C5)F
InChI :
InChI=1S/C26H21F2N5O3/c1-33-15-16(14-30-33)21-11-18(7-10-29-21)36-23-13-19(27)22(12-20(23)28)32-25(35)26(8-9-26)24(34)31-17-5-3-2-4-6-17/h2-7,10-15H,8-9H2,1H3,(H,31,34)(H,32,35)
InChIKey :
WWOXKWLDMLMYQY-UHFFFAOYSA-N
Synonyms :
DCC2618; DCC 2618; c-Kit-IN-1; PDGFR inhibitor 1; N-[2,5-Difluoro-4-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]phenyl]-N'-phenyl-1,1-cyclopropanedicarboxamide
More details are to be found here
Chemos GmbH & Co. KG
Germany
Description : DCC-2618 inhibits normal and mutant KIT kinase at the nanomol level. The targets are wt c-KIT, c-KIT mutants, PDGFR alpha, PDGFR beta, KDR and cFMS. DCC-2618 inhibits mutant KIT in GIST patient cell line (GIST T1 pKIT western Ex11 deletion) at a IC 50 of 2 nM. Deciphera's technology has identified DCC-2618 as a molecule which can be developed as second line therapy for imatinib and sunitinib resistant GIST patients with the potential to progress to frontline GIST therapy. DCC-2618 has been designed to effectively inhibit the imatinib and sunitinib-sensitive KIT juxtamembrane domain mutants (JMD) as well as secondary resistant KIT kinase-domain mutants. DCC-2618 additionally targets PDGFR alpha oncogenic mutants. - Molecular Weight :489.47
- Boiling Point :729.7±60.0 °C at 760 mmHg
- Purity :> 98%
Molecular Formula : C26H21F2N5O3 Canonical SMILES : CN1C=C(C=N1)C2=NC=CC(=C2)OC3=C(C=C(C(=C3)F)NC(=O)C4(CC4)C(=O)NC5=CC=CC=C5)F
InChI :
InChI=1S/C26H21F2N5O3/c1-33-15-16(14-30-33)21-11-18(7-10-29-21)36-23-13-19(27)22(12-20(23)28)32-25(35)26(8-9-26)24(34)31-17-5-3-2-4-6-17/h2-7,10-15H,8-9H2,1H3,(H,31,34)(H,32,35)
InChIKey :
WWOXKWLDMLMYQY-UHFFFAOYSA-N
Synonyms :
DCC2618; DCC 2618; c-Kit-IN-1; PDGFR inhibitor 1; N-[2,5-Difluoro-4-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]phenyl]-N'-phenyl-1,1-cyclopropanedicarboxamide
More details are to be found here
Detailed information on the suppliers of
c-Kit-IN-1 |
details
details